the revolutionary drug Acoramidis, a breakthrough FDA-approved treatment for Transthyretin Amyloid Cardiomyopathy (ATTR-CM), exploring its inspiring development journey from Stanford’s labs to clinical success. Learn how scientists like Dr. Isabella Graef and Dr. Mamun Alhamadsheh designed this TTR stabilizer to combat a rare, life-threatening heart disease, its impressive clinical trial results showing improved survival and reduced hospitalizations, and key pharmacological details from dosing to drug interactions. Discover the collaborative efforts behind this medical milestone and why Acoramidis represents hope for patients and a triumph of translational science. Tune in for a compelling blend of innovation, perseverance, and lifesaving medicine!
The Link to the Drive that contains picture of the T-4 Binding Site : https://drive.google.com/drive/folders/1_L-TB8-LrtEXKdvO8ZWyszspqpup2-kx?usp=sharing
Tape here to discover me on social media: https://taplink.cc/abdelghaniabdelli
Some of our Bibliographic Ressources in cas you wanna deep your searches on Acoramidis:
https://med.stanford.edu/news/all-news/2024/11/spark-acoramidis.html
https://www.nejm.org/doi/full/10.1056/NEJMoa2305434
https://www.drugs.com/monograph/acoramidis.html
https://go.drugbank.com/drugs/DB17999
https://pubmed.ncbi.nlm.nih.gov/38197816/